Health Canada has approved Mylan and Biocon’s trastuzumab biosimilar, Ogivri, referencing Herceptin. The product, also approved in the United States, the European Union, and elsewhere, is the first biosimilar trastuzumab to be approved in Canada, and carries indications for HER2-positive breast cancer and HER2-positive metastatic stomach cancer.
Health Canada has approved Mylan and Biocon’s trastuzumab biosimilar, Ogivri, referencing Herceptin. The product, also approved in the United States, the European Union, and elsewhere, is the first biosimilar trastuzumab to be approved in Canada, and carries indications for HER2-positive breast cancer and HER2-positive metastatic stomach cancer.
Mylan has indicated that it plans to launch Ogivri in Canada during the current quarter of 2019, and it anticipates being the first company to offer a biosimilar trastuzumab to Canadian patients.
Christiane Hamacher, PhD, chief executive officer of Biocon Biologics, said in a statement regarding the approval, “Thousands of patients in Europe, India, and key emerging markets are benefitting from our biosimilar trastuzumab. Biocon Biologics is committed to [addressing] unmet patient needs through its high quality, affordable biologics globally.”
The Canadian approval was based on a data package that included structural and functional characterization; nonclinical studies and a pharmacokinetic evaluation in healthy volunteers and in patients; and a safety, efficacy, and immunogenicity study in patients that compared the biosimilar to the reference product. The data demonstrated that Ogivri is highly similar to Herceptin, with no clinically meaningful differences in terms of efficacy, safety, purity and potency, say the biosimilar developers.
The Canadian Agency for Drugs and Technologies in Health, or CADTH, Canada’s health technology assessment body, lists the biosimilar as currently under funding review for both a 150 mg vial and 440 mg vial. Mylan Chief Commercial Officer Tony Mauro said in a statement that the company looks forward to “continuing our reimbursement discussions with [CADTH] and the Pan-Canadian Pharmaceutical Alliance to ensure that patients have access to Ogivri.”
In the United States, patients continue to wait for access to a biosimilar trastuzumab option; in addition to Mylan and Biocon’s Ogivri, the FDA has also approved Celltrion’s Herzuma, Samsung Bioepis’ Ontruzant, and Pfizer’s Trazimera. None of these products have launched yet in the US marketplace.
However, Roche, maker of the reference Herceptin, predicted in a 2018 earnings call that it would face its first biosimilar trastuzumab competition in the US market in the second half of 2019.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.